Discover six RNAi biotech companies helping to drive momentum in a field that can precisely target disease at its genetic root.
The era of genetic medicine has arrived. As scientists continue to unravel the mysteries of humanity’s genetic blueprint, their discoveries are driving the emergence of new types of therapies such as ...
The United States Food and Drug Administration has just approved the first-ever clinical trial that uses CRISPR-Cas13 RNA editing. Its aim is to treat an eye disease called wet age-related macular ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results